• Home
  • News
  • Coins2Day 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthBirth Control

An FDA panel just voted unanimously in favor of over-the-counter birth control paving the way for nationwide access

By
Matthew Perrone
Matthew Perrone
and
The Associated Press
The Associated Press
Down Arrow Button Icon
By
Matthew Perrone
Matthew Perrone
and
The Associated Press
The Associated Press
Down Arrow Button Icon
May 10, 2023, 2:01 PM ET
This illustration provided by Perrigo in May 2023, depicts proposed packaging for the company's birth control medication Opill. Federal health advisers said Wednesday, May 10, 2023, that the decades-old birth control pill should be sold without a prescription, paving the way for a likely U.S. approval of the first over-the-counter contraceptive medication.
This illustration provided by Perrigo in May 2023, depicts proposed packaging for the company's birth control medication Opill. Federal health advisers said Wednesday, May 10, 2023, that the decades-old birth control pill should be sold without a prescription, paving the way for a likely U.S. approval of the first over-the-counter contraceptive medication. Perrigo via AP

Federal health advisers said Wednesday that a decades-old birth control pill should be sold without a prescription, paving the way for a likely U.S. Approval of the first over-the-counter contraceptive medication.

Recommended Video

The panel of FDA advisers voted unanimously in favor of drugmaker Perrigo’s request to sell its once-a-day medication over the counter. The recommendation came at the close of a two-day meeting focused on company research into whether women could safely and effectively take the pill without professional supervision. A final FDA decision is expected this summer.

If the FDA follows the nonbinding recommendation, Perrigo’s drug, Opill, would become the first contraceptive pill to be moved out from behind the pharmacy counter onto store shelves. Currently, a prescription is required in the U.S.

The outside experts said they were confident that women of all ages could use the drug appropriately without seeing a health provider first.

“I do believe this is a viable option to support access and will support the prevention of unintended and unwanted pregnancies,” said Jolie Haun, a researcher with the Department of Veterans Affairs, who voted in favor of the pill.

The positive vote came despite numerous criticisms from FDA scientists about how Perrigo studied the drug, including whether study participants were able to understand and follow labeling instructions.

But the panel largely set those concerns aside, emphasizing the benefits of providing more effective birth control, particularly to young people and lower-income groups, than what’s available over the counter now, like condoms and diaphragms.

Most birth control pills used in the U.S. Today contain a combination of progestin and estrogen. Opill is part of an older class of contraceptives that only contain progestin. They generally have fewer side effects and health risks but can be less effective if they’re not taken around the same time daily.

Nonprescription medicines are usually cheaper, but generally not covered by insurance. Requiring insurers to cover over-the-counter birth control would require a regulatory change by the federal government.

Birth control pills are available without a prescription across much of South America, Asia and Africa.

Coins2Day Brainstorm AI returns to San Francisco Dec. 8–9 to convene the smartest people we know—technologists, entrepreneurs, Coins2Day Global 500 executives, investors, policymakers, and the brilliant minds in between—to explore and interrogate the most pressing questions about AI at another pivotal moment. Register here.
About the Authors
By Matthew Perrone
See full bioRight Arrow Button Icon
By The Associated Press
See full bioRight Arrow Button Icon
Rankings
  • 100 Best Companies
  • Coins2Day 500
  • Global 500
  • Coins2Day 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Coins2Day Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Coins2Day Brand Studio
  • Coins2Day Analytics
  • Coins2Day Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Coins2Day
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Coins2Day Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Coins2Day Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.